Litigation Details for Janssen Products LP v. Cipla Ltd. (D. Del. 2015)

Janssen Products LP v. Cipla Ltd. (D. Del. 2015)

Docket	1:15-cv-00307	Date Filed	2015-04-10
Court	District Court, D. Delaware	Date Terminated	2015-05-04
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	7,700,645; 8,518,987
Link to Docket	External link to docket

Details for Janssen Products LP v. Cipla Ltd. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-04-10				External link to document
2015-04-10	5		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,700,645 B2; 8,518,987 B2; 7,126,015…April 2015 4 May 2015 1:15-cv-00307 830 Patent None District Court, D. Delaware	External link to document

Janssen Products LP v. Cipla Ltd. Litigation Summary and Patent Analysis, 1:15-cv-00307

Last updated: August 3, 2026

Janssen Products LP v. Cipla Ltd., No. 1:15-cv-00307, was an Abbreviated New Drug Application litigation involving generic rivaroxaban, marketed as Xarelto. Janssen and Bayer asserted Xarelto-related patents after Cipla notified the companies of an ANDA filing. The case ended without a reported trial judgment resolving patent validity or infringement. Its commercial significance was the timing of Cipla's potential generic entry against Xarelto's remaining method-of-use patent protection.

What drug and ANDA were at issue in Janssen v. Cipla?

The dispute involved rivaroxaban tablets, the active ingredient in Xarelto. Xarelto is an oral factor Xa inhibitor developed by Bayer and commercialized in the United States with Janssen.

Item	Information
Brand	Xarelto
Active ingredient	Rivaroxaban
Dosage forms at issue	Rivaroxaban tablets
NDA holder	Janssen Pharmaceuticals, Inc.
Commercial partners	Janssen and Bayer
Generic pathway	ANDA under Hatch-Waxman
Defendant	Cipla Ltd.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-00307
Case type	Paragraph IV patent litigation

Cipla's ANDA was directed to a generic version of Xarelto. The filing triggered the Hatch-Waxman litigation process after Cipla certified that one or more Orange Book patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Janssen filed suit within the statutory 45-day period, which imposed an automatic FDA approval stay. (Janssen Products LP v. Cipla Ltd., No. 1:15-cv-00307, D. Del.)

What patents protected Xarelto in the Cipla litigation?

The principal Xarelto patents associated with the litigation were U.S. Patent Nos. 7,157,456 and 7,592,339.

Patent	General subject matter	Relevance to Xarelto	Original expiration profile
U.S. 7,157,456	Rivaroxaban compound and related pharmaceutical protection	Core active-ingredient patent	Expired in 2020, subject to applicable pediatric exclusivity
U.S. 7,592,339	Methods of treating thromboembolic disorders with rivaroxaban	Method-of-use protection	Expired in 2024, subject to applicable pediatric exclusivity

The '456 patent was the principal composition-of-matter barrier. Once that patent expired, a generic manufacturer could generally market rivaroxaban if it avoided enforceable method-of-use claims or relied on an appropriate section viii statement.

The '339 patent was commercially important because it covered treatment methods associated with Xarelto's approved indications. Its remaining term extended beyond the compound patent and created a potential barrier to unrestricted generic substitution.

Patent scope and listing status must be distinguished. A patent can be listed in the Orange Book while individual claims remain vulnerable to invalidity or noninfringement arguments. The Orange Book identifies patents submitted by the NDA holder, but it does not independently determine enforceability or claim scope. (U.S. Food and Drug Administration, 2025a)

When did Xarelto lose exclusivity?

Xarelto lost its principal compound-patent protection in 2020. The later-expiring method-of-use patent extended patent-related market protection into 2024, with pediatric exclusivity potentially extending applicable periods by six months.

The relevant sequence was:

Date or period	Event
2015	Cipla filed an ANDA certification challenging Xarelto patent protection
2015	Janssen initiated Delaware Hatch-Waxman litigation
2020	Core rivaroxaban compound patent expired
2024	Later method-of-use patent term ended, subject to applicable pediatric extension
2025	FDA-approved pediatric exclusivity periods associated with Xarelto became relevant to generic approval timing
After patent and exclusivity expiry	Unrestricted generic entry became possible, subject to FDA approval and settlement terms

Xarelto's loss of compound-patent protection did not automatically produce immediate, unrestricted generic substitution. FDA approval timing, pediatric exclusivity, method-of-use claims, settlement provisions, and state substitution rules remained relevant.

What were the Paragraph IV issues in the case?

Cipla's ANDA challenge placed the validity and infringement of the asserted Xarelto patents in dispute. The principal Paragraph IV issues would have included:

1. Whether Cipla's proposed rivaroxaban product infringed the asserted compound or method claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether the patents were enforceable.
4. Whether Cipla's labeling would induce infringement of patented treatment methods.
5. Whether a section viii carve-out could avoid infringement of particular method-of-use claims.

For the compound patent, Cipla's central commercial objective would have been to establish that its generic rivaroxaban product could launch after patent expiry. For the method-of-use patent, the more important issue was whether Cipla could use a skinny label that omitted patented indications.

A section viii carve-out does not eliminate all litigation risk. If the generic label, promotional materials, distribution practices, or prescribing environment encourage use of a patented indication, the brand company may assert induced infringement. The scope of the carve-out therefore affects launch timing and the degree of substitution available to pharmacies.

What was the litigation outcome in Janssen Products LP v. Cipla?

The case did not produce a reported merits decision comparable to a bench trial judgment or Federal Circuit appeal. The docket reflects a Hatch-Waxman dispute that concluded through termination rather than a publicly reported adjudication of the asserted Xarelto patents.

The practical outcome was therefore different from a judgment holding the patents valid and infringed. The public record does not establish that:

• the asserted patents were finally adjudicated valid;
• Cipla's ANDA product was finally adjudicated infringing;
• the patents were invalidated;
• Cipla received a court-ordered launch date; or
• the court entered a publicly reasoned injunction after trial.

The case should be classified as resolved without a reported merits determination. Any settlement terms governing Cipla's launch timing, supply restrictions, licensing rights, or authorized-generic arrangements should not be inferred from the dismissal alone. A Hatch-Waxman dismissal can reflect a private settlement, a negotiated launch license, abandonment of the ANDA, or another resolution.

Did Janssen and Cipla enter a settlement agreement?

The public docket conclusion indicates that the case was terminated without a reported trial judgment. The publicly available case record does not provide a complete commercial description of any private settlement terms.

The key settlement questions for diligence are:

Issue	Publicly established from the case disposition?
Cipla's agreed launch date	Not established by the dismissal alone
Authorized-generic supply rights	Not established
Royalty obligations	Not established
Patent license scope	Not established
Payment or reverse-payment terms	Not established
ANDA approval restrictions	Not established
Antitrust review outcome	Not established

A dismissal should not be treated as a finding that Janssen's patents were strong or that Cipla's invalidity arguments were weak. It indicates that the parties ended the dispute without a publicly reported judicial resolution.

What is the Orange Book status of Xarelto?

The FDA Orange Book historically listed Xarelto-related patents, including the compound and method-of-use patents associated with rivaroxaban. Current status must be assessed by patent number, dosage form, indication, and applicable exclusivity period rather than by the brand's continued commercial availability.

Xarelto's Orange Book protection had two distinct phases:

Core compound protection

The compound patent provided the strongest barrier to a conventional generic rivaroxaban product. Its expiration materially reduced the legal risk of manufacturing the active ingredient and selling standard tablet strengths.

Method-of-use protection

The later method patent created a narrower but commercially relevant barrier. It could restrict labeling or use for specific thromboembolic indications even after the compound patent expired.

FDA approval of an ANDA also depends on whether the applicant submits a paragraph III certification, paragraph IV certification, or section viii statement for each listed patent. The FDA does not resolve the underlying patent dispute as part of the ANDA review. (U.S. Food and Drug Administration, 2025a, 2025b)

How strong was Janssen's Xarelto patent estate?

Janssen's Xarelto estate was strongest before expiry of the composition patent. After 2020, its strength depended more heavily on method-of-use enforcement and the ability to separate patented from nonpatented indications.

Estate component	Relative strength after 2020
Core rivaroxaban compound patent	Low after expiration
Broad tablet formulation protection	Limited if not supported by an unexpired listed patent
Method-of-use protection	Moderate, depending on claim scope and generic labeling
Manufacturing-process protection	Potentially relevant but less effective against a noninfringing ANDA product
Pediatric exclusivity	Regulatory timing protection, not a patent right
Brand and clinical adoption	Commercially strong but not a substitute for patent protection

The estate's post-expiry value was therefore concentrated in indication management, regulatory exclusivity, formulation or process patents with enforceable claims, and settlement control.

What generic entry risks existed for Xarelto?

The main generic-entry scenarios were:

1. Full-label entry after all relevant patents and exclusivities expired. This created the highest substitution risk for Janssen and Bayer.
2. Partial-label entry through a section viii carve-out. Cipla could potentially omit patented indications while marketing for unpatented uses.
3. Licensed early entry under a settlement. A negotiated date could precede the last patent expiry.
4. At-risk launch. Cipla could launch before final resolution, exposing itself to damages and injunction risk if the brand prevailed.
5. Delayed or abandoned launch. FDA approval would not guarantee commercialization.

A generic rivaroxaban launch would have affected Xarelto prescriptions, pharmacy substitution, payer formulary positioning, and net pricing. The risk would have increased after compound-patent expiry because the most effective barrier to immediate competition had ended.

Which companies challenged Xarelto patents?

Xarelto faced broad generic interest from multiple ANDA applicants, including Cipla and other manufacturers. The precise litigation posture varied by defendant, patent, dosage form, and settlement.

Generic challengers typically targeted:

• the rivaroxaban compound patent;
• method-of-use patents;
• formulation and dosage claims;
• pediatric and indication-specific exclusivity;
• the feasibility of a section viii label carve-out.

The presence of several ANDA filers increased the probability that at least one manufacturer would reach a commercial resolution capable of setting a market launch date.

How did Xarelto compare with other Janssen products?

Xarelto differed from products protected primarily by complex formulations or long-acting delivery systems. Rivaroxaban is a small molecule with a relatively conventional oral tablet. Its principal legal barrier was the active-ingredient patent, followed by narrower method-of-use protection.

Product type	Main entry barrier	Typical generic risk
Xarelto tablets	Compound and method patents	High after compound expiry
Long-acting injectable products	Formulation, device, manufacturing, and method patents	More difficult to design around
Biologic products	Biologics Price Competition and Innovation Act pathway, manufacturing know-how, patents	Biosimilar and interchangeability issues
Combination products	Multiple active ingredients and formulation claims	Depends on claim breadth

Xarelto did not face a biosimilar pathway because rivaroxaban is a small molecule. The relevant pathway was ANDA approval, not a 351(k) biosimilar application.

What manufacturing and IP barriers remained?

After compound-patent expiry, manufacturing barriers were comparatively limited for a conventional oral rivaroxaban tablet. A generic company still needed:

• validated API sourcing;
• bioequivalence data;
• compliant tablet manufacturing;
• stability data;
• FDA-approved labeling;
• supply-chain qualification; and
• control of crystallinity, impurities, and dissolution performance.

These technical requirements can delay launch, but they generally do not provide the same exclusionary effect as an unexpired composition patent. Process patents can matter where they cover a necessary manufacturing route, but a generic manufacturer may avoid infringement by using a different process.

Key Takeaways

• Janssen Products LP v. Cipla Ltd., No. 1:15-cv-00307, was a Delaware Hatch-Waxman case involving Cipla's generic rivaroxaban ANDA.
• The dispute concerned Xarelto-related patent protection, including U.S. Patent Nos. 7,157,456 and 7,592,339.
• The compound patent expired in 2020; later method-of-use protection extended into the 2024 period, subject to pediatric exclusivity.
• The case ended without a reported merits judgment determining patent validity or infringement.
• The public dismissal does not establish Cipla's launch date, settlement economics, royalty terms, or license scope.
• Generic entry risk increased sharply after compound-patent expiry and depended on method-of-use labeling, FDA exclusivity, and any private settlement terms.
• Xarelto faced generic, not biosimilar, competition because rivaroxaban is a small-molecule drug.

FAQs About Janssen v. Cipla and Xarelto Generic Entry

Was Cipla found to infringe the Xarelto patents?

No reported merits decision in the case establishes that Cipla was found to infringe the asserted patents.

Did the case invalidate Janssen's Xarelto patents?

No. The case disposition did not produce a reported invalidity judgment against the asserted patents.

Could Cipla launch generic rivaroxaban before every Xarelto patent expired?

Potentially, if Cipla obtained a license, relied on a permitted section viii carve-out, or launched under another settlement mechanism. The dismissal alone does not identify which mechanism applied.

Is Xarelto exposed to biosimilar competition?

No. Xarelto is a small-molecule drug and is subject to the ANDA generic pathway rather than the FDA biosimilar pathway.

What is the most important remaining Xarelto patent issue?

The principal post-compound-expiry issue was method-of-use protection and whether a generic label could omit patented indications without creating induced-infringement exposure.

References

1. Janssen Products LP v. Cipla Ltd., No. 1:15-cv-00307, U.S. District Court for the District of Delaware. Public docket record.

2. U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. Washington, DC: Author.

3. U.S. Food and Drug Administration. (2025b). Xarelto (rivaroxaban) prescribing information. Washington, DC: Janssen Pharmaceuticals, Inc.

4. U.S. Patent No. 7,157,456. Oxazolidinones and their use as medicaments. U.S. Patent and Trademark Office.

5. U.S. Patent No. 7,592,339. Methods of treating thromboembolic disorders. U.S. Patent and Trademark Office.